AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN ...

The Second Circuit revived an antitrust case Wednesday against AstraZeneca Plc and three other pharmaceutical firms, saying ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

The completion of this study could positively impact AstraZeneca’s stock performance by enhancing investor confidence in their oncology pipeline. As the company continues to innovate in cancer ...

The study tests two treatment regimens: volrustomig plus chemotherapy (carboplatin with either pemetrexed or paclitaxel) and pembrolizumab plus the same chemotherapy options. Volrustomig is an ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

T-cell engagers (TCEs) are a new class of immuno-oncology therapies that have proven effective for the treatment of both ...

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer ...

AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. AstraZeneca PLC (NASDAQ:AZN) is ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” second-quarter 2025 investor ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

AstraZeneca PLC agreed to buy Fusion Pharmaceuticals Inc. for as much as US$2.4 billion as it seeks to transform cancer treatment by replacing traditional methods like chemotherapy with more targeted ...